MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

105.25

-0.38%↓

WBA

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

105.25

-0.38%↓

WBA

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

105.25

-0.38%↓

WBA

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

105.25

-0.38%↓

WBA

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

105.25

-0.38%↓

WBA

+0.36%↑

CHE

545.53

-2.68%↓

Kodu・Aktsiate loetelu・ENANTA PHARMACEUTICALS INC

ENANTA PHARMACEUTICALS INC

Suletud

SektorTervishoid

5.65 1.07

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

5.28

Max

5.65

Põhinäitajad
By Trading Economics
Sissetulek	94M -22M
Müük	-51M 17M
Aktsiakasum	-1.05
Kasumimarginaal	-131.435
Töötajad	131
EBITDA	-20M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+157.14% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. mai 2025

Turustatistika
By TradingEconomics
Turukapital	112M
Eelmine avamishind	4.58
Eelmine sulgemishind	5.65

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

5.225 / N/A Toetus ja vastupanu

ENANTA PHARMACEUTICALS INC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. apr 2025, 23:54 UTC

Kuumad aktsiad

Stocks to Watch: Alphabet, Intel, AppFolio

24. apr 2025, 23:51 UTC

Market Talk

Gold Edges Higher, Supported by U.S. Dollar Weakness -- Market Talk

24. apr 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. apr 2025, 23:46 UTC

Market Talk

Nikkei May Rise on Hopes for Easing U.S.-China Trade Tensions -- Market Talk

24. apr 2025, 23:37 UTC

Peamised uudised

Big Tech Braces for Tariff-Induced Advertising Slowdown -- WSJ

24. apr 2025, 23:36 UTC

Peamised uudised

Tokyo Consumer Inflation Accelerates in April as Companies Raise Prices

24. apr 2025, 23:13 UTC

Peamised uudised

Tulu

Google's Earnings Power Holds Up in Global Turbulence -- Update

24. apr 2025, 23:09 UTC

Peamised uudised

Trump Initiatives Knocked Back in a New Round of Court Rulings -- 2nd Update

24. apr 2025, 23:02 UTC

Omandamised, ülevõtmised, äriostud

SK Telecom to Sell 10.8M Kakao Shares via After-Hours Block Trading

24. apr 2025, 23:02 UTC

Omandamised, ülevõtmised, äriostud

SK Telecom to Dispose of 2.4% Stake in Kakao to Raise KRW413.27B

24. apr 2025, 22:51 UTC

Peamised uudised

Omandamised, ülevõtmised, äriostud

Germany's Merck Nears Roughly $3.5 Billion Deal for SpringWorks -- Update

24. apr 2025, 22:48 UTC

Peamised uudised

Walmart Walks the DEI Tightrope in Latest Proxy Statement -- Barrons.com

24. apr 2025, 22:47 UTC

Market Talk

Intel Remains in Tough Position, CFRA Research Analyst Says -- Market Talk

24. apr 2025, 22:38 UTC

Market Talk

Tulu

Tariffs Hurt Intel's 2Q Outlook as CFO Warns Economic Slowdown is Likely -- Market Talk

24. apr 2025, 22:24 UTC

Tulu

Aluminum Corp. of China: Increase in Product Sales Supported 1Q Results >2600.HK

24. apr 2025, 22:24 UTC

Tulu

Aluminum Corp. of China 1Q Rev CNY55.78B Vs. CNY48.96B >2600.HK

24. apr 2025, 22:24 UTC

Market Talk

Tulu

Intel's Comeback Involves More Engineers, More In-Office Work -- Market Talk

24. apr 2025, 22:23 UTC

Tulu

Aluminum Corp. of China 1Q Net CNY3.54B Vs. Net CNY2.23B >2600.HK

24. apr 2025, 22:11 UTC

Market Talk

Tulu

Global Equities Roundup: Market Talk

24. apr 2025, 22:11 UTC

Market Talk

Tulu

Intel CEO: Layoffs Will Simplify Company Structure -- Market Talk

24. apr 2025, 22:09 UTC

Peamised uudised

Tulu

Intel Cuts Outlook, Says Layoffs Are in Store -- Update

24. apr 2025, 22:00 UTC

Market Talk

Tulu

T-Mobile's Key Subscriber Metric Disappoints Despite Earnings Beat -- Market Talk

24. apr 2025, 21:39 UTC

Peamised uudised

Trump Initiatives Knocked Back in a New Round of Court Rulings -- WSJ

24. apr 2025, 21:24 UTC

Peamised uudised

Tulu

Bristol Myers Reports Better-Than-Expected Earnings. The Future Is Cloudy. -- Barrons.com

24. apr 2025, 21:24 UTC

Peamised uudised

Tulu

Google's Earnings Power Holds Up in Global Turbulence -- WSJ

24. apr 2025, 21:23 UTC

Peamised uudised

Tulu

Intel Cuts Outlook, Says Layoffs Are in Store -- WSJ

24. apr 2025, 21:04 UTC

Tulu

T-Mobile Reports Strong Earnings but Its Wireless Results Disappoint. The Stock Is Sliding. -- Barrons.com

24. apr 2025, 21:03 UTC

Tulu

Agnico-Eagle Mines Believes Its Rev Structure Will Be Largely Unaffected by the Tariffs >AEM.T

24. apr 2025, 21:03 UTC

Tulu

Agnico-Eagle Mines Total Expected Capex for 2025 Still Estimated at $1.75 B to $1.95 B >AEM.T

24. apr 2025, 21:02 UTC

Tulu

Agnico-Eagle Mines Positioned to Achieve 2025 AISC Per Ounce Guidance of $1,250 to $1,300. >AEM.T

Võrdlus sarnastega

Hinnamuutus

ENANTA PHARMACEUTICALS INC Prognoos

Hinnasiht

By TipRanks

157.14% tõus

12 kuu keskmine prognoos

Keskmine 14.4 USD 157.14%

Kõrge 21 USD

Madal 5 USD

Põhineb 5 Wall Streeti analüütiku instrumendi ENANTA PHARMACEUTICALS INC 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi ENANTA PHARMACEUTICALS INC aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

5.225 / N/AToetus ja vastupanu

Recent bullish events outweigh bearish events.

Bearish events outweigh bullish events.

There is one bearish event.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest ENANTA PHARMACEUTICALS INC

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.